CRSP - What Does It Mean for Investors if CRISPR Therapeutics Gets Bought Out in 2024?
2024-01-14 13:30:00 ET
CRISPR Therapeutics (NASDAQ: CRSP) has put itself on the map of the healthcare industry as a serious player in gene editing. Now that it has an approved treatment in Casgevy, there's undoubtedly going to be more of a spotlight on the company.
Gene-therapy treatments are growing in popularity, and for a larger healthcare company that is perhaps looking into getting into the business, it could be more attractive to simply buy CRISPR Therapeutics than to develop its own therapies.
Here's why CRISPR could be an attractive acquisition target, and what it would mean for investors if the company is bought out this year.
For further details see:
What Does It Mean for Investors if CRISPR Therapeutics Gets Bought Out in 2024?